Combining immune therapies to improve treatment for advanced liver cancer
Project 3
This study is looking at a new way to help people with advanced liver cancer who haven't had success with standard treatments by combining two types of therapies that boost the immune system to fight the cancer better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10935707 on NIH RePORTER |
What this research studies
This research investigates the use of a combination of immune checkpoint blockade and oncolytic virus therapy to enhance treatment outcomes for patients with advanced Hepatocellular Carcinoma (HCC). The approach aims to overcome the limitations of current therapies by promoting immune responses within the tumor microenvironment. Patients who have not responded to first-line treatments may benefit from this innovative strategy, which has shown promise in early trials. The research involves both human studies and preclinical models to evaluate the effectiveness of these combined therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced Hepatocellular Carcinoma who have not responded to initial immune therapies.
Not a fit: Patients with early-stage liver cancer or those who have not undergone prior immune therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment options for patients with advanced liver cancer.
How similar studies have performed: Previous research has shown promising results with similar combinations of immune therapies, indicating potential for success in this novel approach.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Vile, Richard G. — Mayo Clinic Rochester
- Study coordinator: Vile, Richard G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.